Home

Loading...

Table of contents

Gastric cancer

What's new

Updated 2023 SITC guidelines for the use of immunotherapy in gastric cancer.

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of gastric cancer are prepared by our editorial team based on guidelines from the American Academy of Family Physicians (AAFP 2023), the American College of Gastroenterology (ACG 2023,2017,2015), the American Society of Clinical Oncology (ASCO 2023), the Society for Immunotherapy of Cancer (SITC 2023), the British Society of Gastroenterology (BSG 2022,2019),...
Show more

Screening and diagnosis

Indications for screening, asymptomatic patients: as per ESMO 2022 guidelines, Obtain population-based endoscopic screening in asymptomatic persons only in regions with a very high incidence of gastric cancer.
B
Create free account

More topics in this section

  • Indications for screening (familial cancer syndromes)

  • Indications for testing

Classification and risk stratification

Staging: as per ESMO 2022 guidelines, Perform a physical examination, obtain CBC with differential, liver and renal function tests, contrast-enhanced CT of the chest, abdomen ± pelvis, and perform upper gastrointestinal endoscopy for initial staging and risk assessment.
B
Show 2 more

Diagnostic investigations

Testing for H. pylori infection: as per ACG 2017 guidelines, Test for H. pylori infection in all patients with low-grade gastric MALT lymphoma, or a history of endoscopic resection of early gastric cancer.
B
Show 2 more

Diagnostic procedures

Biopsy: as per ESGE 2021 guidelines, Take at least 6 biopsies in patients with suspected advanced gastric cancer.
B
Show 3 more

More topics in this section

  • Histopathology

  • Ancillary testing

  • Diagnostic laparoscopy and peritoneal lavage

Medical management

General principles: as per ESMO 2022 guidelines, Ensure multidisciplinary treatment planning before any treatment decision.
B

More topics in this section

  • Management of locoregional disease (perioperative chemotherapy)

  • Management of locoregional disease (adjuvant chemoradiotherapy)

  • Management of advanced/metastatic disease (first-line chemotherapy)

  • Management of advanced/metastatic disease (targeted therapy and immunotherapy)

  • Management of advanced/metastatic disease (liver metastasis)

  • Palliative care

Nonpharmacologic interventions

Nutritional support: as per ESMO 2022 guidelines, Offer dietary support with attention to vitamin and mineral deficiencies in patients with gastric cancer.
B

Therapeutic procedures

Endoscopic gastroduodenal stenting: as per ASGE 2021 guidelines, Consider placing self-expandable metallic stents or performing surgical gastrojejunostomy in patients with incurable malignant gastric outlet obstruction undergoing palliative intervention. Decide between these approaches based on patient characteristics and preferences, multidisciplinary input, and local expertise.
C
Show 2 more

Perioperative care

Patients with hereditary diffuse gastric cancer: as per ACG 2015 guidelines, Include the following in the management of patients with hereditary diffuse gastric cancer:
prophylactic gastrectomy after age 20 years (> 80% risk by age 80)
breast cancer surveillance in females beginning at age 35 years with annual mammography and breast MRI and clinical breast examination every 6 months
colonoscopy beginning at age 40 years in families including colon cancer.
B

Surgical interventions

Surgical resection, locoregional disease: as per ESMO 2022 guidelines, Consider performing endoscopic or surgical resection alone in selected patients with very early tumors (stage IA).
C
Show 2 more

More topics in this section

  • Surgical resection (advanced/metastatic disease)

  • Palliative gastrojejunostomy

Specific circumstances

Patients with precancerous gastric lesions, etiology
As per EHMSG/ESGE/ESP/SPED 2019 guidelines:
Recognize that:
patients with chronic atrophic gastritis or intestinal metaplasia are at risk for gastric adenocarcinoma
A
patients with advanced stages of gastritis, that is, atrophy and/or intestinal metaplasia affecting both antral and corpus mucosa, are at higher risk for gastric adenocarcinoma
B
histologically confirmed intestinal metaplasia is the most reliable marker of atrophy in gastric mucosa
A
Recognize that the management of patients with chronic atrophic gastritis or intestinal metaplasia intends to prevent high-grade dysplasia and invasive carcinoma.
B

More topics in this section

  • Patients with precancerous gastric lesions (upper gastrointestinal endoscopy)

  • Patients with precancerous gastric lesions (EUS)

  • Patients with precancerous gastric lesions (biopsy)

  • Patients with precancerous gastric lesions (serum pepsinogen levels)

  • Patients with precancerous gastric lesions (H. pylori eradication)

  • Patients with precancerous gastric lesions (NSAIDs)

  • Patients with precancerous gastric lesions (antioxidants)

  • Patients with precancerous gastric lesions (endoscopic resection)

  • Patients with precancerous gastric lesions (surgical resection)

  • Patients with precancerous gastric lesions (endoscopic surveillance)

  • Patients with gastrointestinal stromal tumor (diagnosis)

  • Patients with gastrointestinal stromal tumor (EUS)

  • Patients with gastrointestinal stromal tumor (biopsy)

  • Patients with gastrointestinal stromal tumor (mutational analysis)

  • Patients with gastrointestinal stromal tumor (chemotherapy, local/locoregional disease)

  • Patients with gastrointestinal stromal tumor (chemotherapy, advanced/metastatic disease)

  • Patients with gastrointestinal stromal tumor (radiotherapy)

  • Patients with gastrointestinal stromal tumor (surgical excision, local/locoregional disease)

  • Patients with gastrointestinal stromal tumor (surgical excision, advanced/metastatic disease)

  • Patients with gastrointestinal stromal tumor (surveillance imaging)

Follow-up and surveillance

Follow-up: as per ESMO 2022 guidelines, Obtain regular follow-up for investigation and treatment of symptoms, psychological support, and early detection of recurrence.
B
Show 3 more